Isoniazid-resistant tuberculosis: A problem we can no longer ignore.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
entrez:
22
1
2020
pubmed:
22
1
2020
medline:
14
4
2020
Statut:
epublish
Résumé
Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis.
Identifiants
pubmed: 31961857
doi: 10.1371/journal.pmed.1003023
pii: PMEDICINE-D-19-04345
pmc: PMC6974036
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003023Commentaires et corrections
Type : CommentOn
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: MP serves on the editorial boards of PLoS Medicine and PLoS One, and is a co-editor of the PLOS Tuberculosis Channel. He has no financial or industry interests to disclose.
Références
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142
pubmed: 31729908
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):774-782
pubmed: 31439108
Lancet Infect Dis. 2017 Feb;17(2):223-234
pubmed: 27865891
Lancet Respir Med. 2018 Apr;6(4):265-275
pubmed: 29595509
PLoS Med. 2020 Jan 21;17(1):e1003008
pubmed: 31961877
Nat Rev Microbiol. 2019 Sep;17(9):533-545
pubmed: 31209399
Int J Tuberc Lung Dis. 2019 May 1;23(5):535-546
pubmed: 31097060
J Clin Microbiol. 2016 Dec 28;55(1):183-198
pubmed: 27807153
Lancet Infect Dis. 2016 Oct;16(10):1185-1192
pubmed: 27397590
Lancet Public Health. 2019 Aug;4(8):e374
pubmed: 31376856